Rafferty Asset Management
SYRE icon

Rafferty Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Rafferty Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Sell
36,767
-20,153
-35% -$1.47M 0.01% 512
2026
Q1 		$2.87M Buy
56,920
+3,510
+7% +$132K 0.01% 525
2025
Q4 		$1.75M Sell
53,410
-6,257
-10% -$163K 0.01% 679
2025
Q3 		$1M Buy
59,667
+8,710
+17% +$142K ﹤0.01% 791
2025
Q2 		$763K Sell
50,957
-19,366
-28% -$287K ﹤0.01% 802
2025
Q1 		$1.13M Sell
70,323
-6,417
-8% -$134K ﹤0.01% 711
2024
Q4 		$1.79M Buy
76,740
+6,154
+9% +$180K 0.01% 674
2024
Q3 		$2.08M Buy
70,586
+3,477
+5% +$96.8K 0.01% 626
2024
Q2 		$1.58M Buy
+67,109
New +$2.26M 0.01% 705

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rafferty Asset Management's SYRE Position: Q2 2026 in Review

Rafferty Asset Management reduced its Spyre Therapeutics (SYRE) stake by 35% in Q2 2026, selling an estimated $1.47M and leaving 36,767 shares worth $3.26M. The position accounts for 0.01% of the portfolio, ranked #512.

Rafferty Asset Management first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Rafferty Asset Management held 36,767 shares of Spyre Therapeutics worth $3.26M as of Q2 2026.
  • Rafferty Asset Management sold 20,153 Spyre Therapeutics shares in Q2 2026, an estimated $1.47M.
  • Spyre Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #512 holding.
  • Rafferty Asset Management first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.